Medical Cannabis for Menopause UK: Can It Help?

Menopause — the natural cessation of menstruation — affects every woman, typically between the ages of 45 and 55, though perimenopause symptoms can begin years earlier. In the UK, approximately 13 million women are currently peri- or post-menopausal, and the economic and social cost of poorly managed menopause is significant: a 2022 report by the Fawcett Society found that one in ten women left employment due to menopause symptoms, and the NHS spends an estimated £30 million annually on menopause-related GP consultations.

Hormone Replacement Therapy (HRT) remains the gold-standard treatment for many women, and access has improved significantly since the 2022 HRT prescription prepayment certificate was introduced. However, HRT is contraindicated for women with a history of certain hormone-sensitive cancers, blood clots, or liver disease. Others find that HRT does not adequately address the full spectrum of symptoms — particularly sleep disturbance, anxiety, joint pain, and mood dysregulation — leaving a substantial unmet need that is driving growing interest in alternative and complementary approaches, including cannabis-based medicinal products (CBMPs).

The endocannabinoid system (ECS) plays a central role in regulating many of the physiological processes disrupted during menopause. Oestrogen is known to modulate ECS activity — it upregulates cannabinoid receptor expression and influences the production of endocannabinoids such as anandamide. As oestrogen levels decline during perimenopause and menopause, ECS function is correspondingly disrupted, which may contribute directly to the characteristic symptoms of menopause.

This relationship provides a compelling biological rationale for cannabinoid-based intervention. CBD (cannabidiol) interacts with the ECS without causing psychoactive effects, and has demonstrated anxiolytic, anti-inflammatory, and sleep-promoting properties in clinical studies. THC (tetrahydrocannabinol) has established analgesic and sedative effects, which may be particularly relevant for women experiencing chronic joint pain and severe sleep disruption. The two cannabinoids are often used in combination, with the ratio and dosage tailored to the individual patient's symptom profile.

The evidence base for medical cannabis in menopause is still emerging, but several lines of research support its potential utility across the key symptom domains.

Sleep: Sleep disturbance is reported by up to 60% of menopausal women, and it is one of the most robustly supported indications for CBMPs. Multiple clinical studies have found that CBD reduces sleep latency and improves sleep quality, while THC has sedative properties that can be beneficial for women with severe insomnia. Data from the UK Medical Cannabis Registry shows that sleep quality is one of the most consistently improved outcomes across all CBMP patient groups.

Anxiety and mood: CBD has demonstrated significant anxiolytic effects in randomised controlled trials, with a 2019 study in The Permanente Journal finding that 79% of patients with anxiety reported improvement within the first month of CBD treatment. For menopausal women experiencing heightened anxiety, mood swings, and low mood — symptoms driven by declining oestrogen and progesterone — CBD-dominant preparations may offer meaningful relief.

Chronic pain and joint discomfort: Musculoskeletal pain is a frequently underreported menopause symptom, affecting up to 50% of women. Cannabis-based medicines have the strongest evidence base of any CBMP indication for chronic pain, with multiple systematic reviews confirming their efficacy for neuropathic and inflammatory pain. For menopausal women experiencing joint pain, muscle aches, and headaches, this evidence is directly applicable.

Hot flushes: The evidence here is more limited, but preclinical research suggests that CBD may modulate the hypothalamic thermoregulatory pathways involved in hot flushes. Anecdotal reports from patients and early observational data are encouraging, and this is an active area of clinical research.

Medical cannabis is not a first-line treatment for menopause. To be considered for a cannabis-based medicinal product through the UK's treatment-resistant pathway, you will generally need to:

• Have documented menopause or perimenopause symptoms that are significantly affecting your quality of life
• Have tried at least two conventional treatments (such as HRT, SSRIs for mood/anxiety, or sleep medications) without adequate benefit, or have a contraindication to those treatments
• Be aged 18 or over and a UK resident

Because menopause is not a single condition but a cluster of symptoms, the eligibility assessment will focus on your most debilitating symptoms — whether that is sleep disruption, anxiety, chronic pain, or a combination. Your prescribing clinician will tailor the treatment approach accordingly.

Women who cannot take HRT due to a history of hormone-sensitive breast cancer, blood clots, or other contraindications may find that the treatment-resistant pathway is more readily accessible, as conventional options are limited for this group. Our [conditions page](/conditions) provides an overview of the full range of conditions treated with CBMPs at MEDCANN Pharmacy.

The specific formulation prescribed will depend on your dominant symptoms and clinical history. Common approaches include:

CBD-dominant oils for anxiety and mood: A high-CBD, low-THC preparation taken sublingually (under the tongue) is typically the starting point for women whose primary symptoms are anxiety, mood dysregulation, and mild sleep disturbance. These are non-psychoactive and well-tolerated.

Balanced CBD:THC preparations for sleep and pain: For women with significant sleep disruption or musculoskeletal pain, a preparation containing both CBD and THC in a balanced ratio (e.g. 1:1 or 2:1 CBD:THC) may be more effective. These are typically taken in the evening and require careful titration.

THC-dominant preparations for severe insomnia: In cases of severe, treatment-resistant insomnia, a higher-THC preparation may be considered under close clinical supervision. These are used at the lowest effective dose and are not appropriate for daytime use.

All products dispensed by MEDCANN Pharmacy are pharmaceutical-grade CBMPs manufactured to GMP standards. Your pharmacist will provide comprehensive guidance on dosing, administration, and what to expect during the titration period.

The process follows the same pathway as for other conditions:

1. Register as a patient using our online registration form. You will be asked to provide your medical history and details of previous menopause treatments.
2. Book an initial consultation (£200) with one of our specialist clinicians via video call, lasting approximately 30–45 minutes.
3. Receive your prescription. If the clinician determines a CBMP is appropriate, they will issue a private prescription sent directly to MEDCANN Pharmacy.
4. Your medication is dispensed and delivered discreetly and securely to your address anywhere in the UK, typically within 2–3 working days.
5. Ongoing monitoring. Follow-up consultations (£95 per quarter) are required to review your response to treatment and renew your prescription.

If you have questions before registering, our pharmacists are available by phone (0208 123 8883) or email ([email protected]). We understand that navigating menopause treatment options can feel overwhelming, and we are here to help you make an informed decision.

Can I take medical cannabis alongside HRT? In many cases, yes. CBMPs and HRT work through different mechanisms and are not contraindicated together. Your prescribing clinician will review your full medication list and advise on any potential interactions. Many women use CBMPs as a complement to HRT to address residual symptoms such as sleep disruption or anxiety that HRT alone does not fully resolve.

Will medical cannabis affect my hormone levels? CBD and THC do not directly replace or mimic oestrogen or progesterone. They act on the endocannabinoid system rather than the hormonal axis. There is no evidence that CBMPs interfere with HRT or alter hormone levels.

Is medical cannabis for menopause available on the NHS? No. NHS prescriptions for CBMPs for menopause symptoms are not currently available. This is a private treatment. See our [pricing page](/pricing) for a full breakdown of consultation and medication costs.

Will I feel 'high'? CBD-dominant preparations are non-psychoactive. If a THC-containing preparation is prescribed, your clinician will start at the lowest effective dose and titrate slowly. Evening dosing is typically recommended for THC-containing products to minimise any daytime effects.

Can I drive while taking medical cannabis? You must not drive while impaired by any substance. If your prescription contains THC, do not drive until you understand how the medication affects you. See our full guide on [driving and medical cannabis in the UK](/blog/driving-medical-cannabis-uk-law).